MIGDAL HA'EMEQ, Israel, June 5, 2014 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced today that results of its clinical trial on INFAT® (structured fat ingredient for infant nutrition, marketed by Advanced Lipids, a joint venture of AAK and Enzymotec) will be presented at the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Conference on June 9-12, 2014 in Jerusalem, Israel (to read the full scientific abstract go to: http://journals.lww.com/jpgn/Documents/ESPGHAN%202014%20Abstracts%20-%20Complete%20abstracts.pdf Page: 432).
The study is the first to test the effect of a commercial infant formula containing INFAT® and prebiotics compared to the control formula containing standard vegetable oil and prebiotics or breast-fed infants on the well-being of Chinese term infants. The study was conducted in medical centers across China in collaboration with Biostime, a leading infant formula company in China.
The study demonstrated significant benefits of INFAT®, similar to breastfeeding; it may increase infant comfort by reducing crying and enhance fat and nutrient absorption during the first weeks of life compared to the control formula.
"This study further emphasizes the importance of INFAT® as integral part of the infant early nutrition," said Dr. Fabiana Bar-Yoseph of Enzymotec R&D infant nutrition. "And our ongoing commitment to explore the special characteristics and health benefits of INFAT® on various infant populations."
The INFAT® Advanced Lipids team will participate in the ESPGHAN conference and will be glad to answer any questions. Please visit the team at booth R8 for more information.
INFAT® is sold and marketed by Advanced Lipids, a joint venture of AAK and Enzymotec, it is a clinically-proven sn-2 palmitate ingredient that more closely resembles the fat structure and properties of human milk fat.
Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies. The Enzymotec Infant Nutrition division develops lipid compositions that mimic human milk fat to facilitate healthy infant development. For more information, visit www.enzymotec.com.
About Advanced Lipids AB
Advanced Lipids is a joint venture of AAK and Enzymotec that was established for the marketing, sale and distribution of INFAT® to the infant nutrition industry. INFAT® is produced in AAK's state of the art production facilities in Sweden based on proprietary enzymatic technology developed by Enzymotec. For more information, visit www.advancedlipids.com.
Forward Looking Statements
This release may contain forward-looking statements, which express the current beliefs and expectations of Company management. Such statements involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences the following risks: we depend on third parties to obtain raw materials, in particular krill, necessary for the production of our products; a high proportion of the sales of our INFAT® product is sold to end users by a single company in China; we are subject to a degree of customer concentration and our customers do not enter into long-term purchase commitments with us; we may be required to pay royalties on sales of our krill products in North America and Australia; we have in the past, and may in the future, become subject to litigation regarding intellectual property rights or other matters; our offering of products as ''medical foods'' in the United States may be challenged by regulatory authorities; we rely on our Swedish joint venture partner to manufacture INFAT®, and certain matters related to the joint venture are the subject of disagreement; we are dependent on a single facility that houses the majority of our operations; we may be impacted by delays in manufacturing as we expand our capacity; we may not be able to expand our production or processing capabilities or satisfy growing demand; our gross profits may be adversely affected if we are only able to obtain lower quality krill meal; our ability to obtain krill may be affected by conservation regulation or initiatives; our product development cycle is lengthy and uncertain, and our development or commercialization efforts for our products may be unsuccessful; we are subject to significant and increasing government regulations regarding the sale and marketing of our products; we may not be able to protect our proprietary technology or prevent its unauthorized use by third parties; and other factors discussed under the heading "Risk Factors" in the Company's Form 20-F filed with the Securities and Exchange Commission on February 13, 2014. Forward-looking statements in this release are made pursuant to the safe harbor provisions contained in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: ICR, LLC Katie Turner 646-277-1228 -or- John Mills 310-954-1105 John.Mills@icrinc.comSource:Enzymotec Ltd.